MedTrace Logo

MEDUSA Study - Migraine: Evaluation of Diagnosis, Utilisation of Services and Application

NCT05979285 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 887

Last updated 2023-08-07

No results posted yet for this study

Summary

Migraine is a very common condition characterised by frequent severe headaches that are very debilitating. Although the frequency and severity does reduce as patient's age, particularly above the age of 70, in younger and working age people this condition has a significant impact on people's lives. Patients with migraine are typically diagnosed and managed in primary care, but can also be treated by neurologists. Recently, NHS England has published guidance for clinical staff to optimise patient management: reduce admissions to hospital for migraine and improve the setting in which patients are seen. One recommendation is the increased use of headache diaries by patients. These may help patients and doctors to improve migraine diagnosis and its treatment, for example by identifying if there are triggers for getting a migraine attack. With technological advancements, there are now computer/phone applications (Apps) that can be used instead of a paper diary. The Curelator N1 Headache App is one of such migraine specific Apps. In this study, the investigators aim to evaluate if primary care migraine patients are open to using a digital headache diary App, and how compliant users of the App will be. The investigators also aim to assess patient feedback on the use of the N1 Headache App, and if its use aids them in the management of their migraine.

Conditions

Interventions

DEVICE

N1-Headache App (by Curelator)

Digital application allowing patients to monitor their migraines, and to identify triggers and/or protectors for their migraines.

Sponsors & Collaborators

  • Cumbria Partnership NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Stacey J Fisher, MD · substantive employee

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-15
Primary Completion
2021-07-31
Completion
2021-12-20

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05979285 on ClinicalTrials.gov